Skip to main content
Skip to content
1 duplicate copy in the archive
Case File
d-35488House Oversight

Fund Disclosure on Pharmaceutical Policy Risks and Investment Capital Constraints

Other

The passage outlines generic investment risk disclosures and proposed pharmaceutical reforms without naming specific high‑profile individuals, transactions, or novel allegations. It offers limited act Describes potential reforms affecting drug pricing, rebates, and marketing regulations. Notes risk that proposed reforms could reduce fund returns on biopharma investments. Highlights capital constra

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024072
Pages
1
Persons
2
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.